IO Biotech (IO Biotech) Additional Paid-In Capital : $408.15 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Additional Paid-In Capital?

IO Biotech's quarterly additional paid-in capital increased from Sep. 2023 ($405.04 Mil) to Dec. 2023 ($406.59 Mil) and increased from Dec. 2023 ($406.59 Mil) to Mar. 2024 ($408.15 Mil).

IO Biotech's annual additional paid-in capital increased from Dec. 2021 ($319.67 Mil) to Dec. 2022 ($326.71 Mil) and increased from Dec. 2022 ($326.71 Mil) to Dec. 2023 ($406.59 Mil).

IO Biotech Additional Paid-In Capital Historical Data

The historical data trend for IO Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Additional Paid-In Capital Chart

IO Biotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

1.50

1.11

319.67

326.71

406.59

IO Biotech Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial												328.59	330.22	405.04	406.59	408.15

IO Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

IO Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of IO Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

IO Biotech (IO Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200

Website

https://www.iobiotech.com

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Executives

Brian Burkavage	officer: Chief Accounting Officer	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma	10 percent owner	24 RUE ROYALE, PARIS I0 75008
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith	officer: General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad	officer: Chief Medical Officer	1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan	officer: Chief Financial Officer	38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier	director	1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson	director	1209 ORANGE STREET, WILMINGTON DE 19801